Sunshine Silver Mining & Refining saw its shares rise 27% during its debut on the New York Stock Exchange, signaling strong investor interest. AstraZeneca celebrated its transfer to the NYSE, noted as the largest by market capitalization in the exchange's 234-year history. Meanwhile, fintech company RedotPay introduced a new B2B product aimed at cutting global merchant fees by 70%. These developments highlight active market movements and innovation ahead of trading sessions.
AstraZeneca PLC shares fell over 6% following the failure of Wainua (eplontersen) in its Phase 3 ATTR-CM trial, which represents a significant lost revenue opportunity. Ionis Pharmaceuticals, which developed eplontersen and stands to earn royalties, ...
The FTSE 100 fell due to AstraZeneca's 8% drop after a failed clinical trial for a heart disease drug, impacting its market value by £20 billion. Meanwhile, Computacenter surged over 13% following a strong trading update, and US semiconductor stocks ...
AstraZeneca's drug Wainua failed a key trial, causing its shares to fall 9%, the largest drop in the FTSE 100 that day. Jefferies notes the impact on the stock price exceeds the drug's actual valuation contribution, which is about 2% of net present v...
AstraZeneca and Ionis Pharmaceuticals saw their shares drop after their jointly developed heart disease drug, Wainua, failed a late-stage trial. The drug, designed as a monthly gene silencer injection, did not show a statistically significant benefit...
AstraZeneca's shares fell 9.55%, wiping £19 billion off its value, after its Wainua drug failed a major Phase III trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial did not meet its primary goal of reducing cardiovascular de...
